Skip to content

Inspection Record

Central Glass Co., Ltd. — FDA 483 Findings

US FDAInspected 2023-09-15Published 2026-11-05 6 findingsValidation and qualificationMaterial and supplier controlLaboratory and QC controlsRegulatory reporting and change controlCleaning validationOther quality system

Inspectors Teresa I. NavasThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Validation and qualification

Your validation protocols for the execution ofrevalidation studies do not specify critical process steps.

2Material and supplier control

Your receiving procedures for raw materials are inadequate.

4Regulatory reporting and change control

Changes that could affect the production and control of the intermediate or API are not always handled using the formal change control system.

5Cleaning validation

Your cleaning procedures are not validated.

6Other quality system

Specifications of Water used in the manufacture of APIs do not demonstrate the water is suitable for its intended use.

A record as of the US FDA document published on 2026-11-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Central Glass Co., Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.